KSHV's impact on iron metabolism and cell death pathways for new treatment options.
KSHV Manipulates Host Iron Metabolism and Ferroptotic Cell Death Pathways, Creating Novel Vulnerability Points for Therapeutic Intervention.
This study is looking at how the Kaposi sarcoma virus affects iron levels and cell death in the body, with the goal of finding new ways to treat Kaposi sarcoma, especially for people with weakened immune systems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11075124 on NIH RePORTER |
What this research studies
This research investigates how the Kaposi sarcoma herpesvirus (KSHV) alters iron metabolism and cell death pathways in host cells, particularly focusing on its effects on ferroptosis, a type of cell death linked to oxidative stress. By understanding these interactions, the research aims to identify new therapeutic targets that could lead to more effective treatments for Kaposi sarcoma, especially in patients with compromised immune systems. The study employs advanced molecular techniques to analyze the changes in host cell behavior caused by KSHV infection, which could reveal vulnerabilities that can be exploited for therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Kaposi sarcoma or those infected with KSHV, particularly those with compromised immune systems.
Not a fit: Patients who do not have Kaposi sarcoma or are not infected with KSHV may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel and effective treatments for Kaposi sarcoma, improving outcomes for patients affected by this cancer.
How similar studies have performed: Other research has shown promise in targeting viral interactions with host cell pathways, suggesting that this approach could yield significant advancements in treatment.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Skalsky, Rebecca L — Oregon Health & Science University
- Study coordinator: Skalsky, Rebecca L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.